Drug intelligence / Profile preview

Clostridium botulinum toxin type A (DWP712)

Development stage: Phase 3
Lead developer: Daewoong Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

DWP712 is a formulation of clostridium botulinum toxin type A under development by Daewoong Pharmaceutical for the treatment of glabellar lines (frown lines). Its mechanism of action involves inhibition of synaptosomal-associated protein 25 (SNAP25), which blocks acetylcholine release at neuromuscular junctions, resulting in temporary muscle paralysis and reduction in dynamic facial wrinkles. The drug has completed Phase 1 clinical trials for glabellar lines. It is not yet approved in any country[2][5][7].

Other names: DWP-712DWP712DWP 712clostridium botulinum toxin

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on Clostridium botulinum toxin type A (DWP712).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridium botulinum toxin type A (DWP712).

Explore the full profile